FR2963241B1 - Vaccin contre le paludisme gestationnel - Google Patents

Vaccin contre le paludisme gestationnel

Info

Publication number
FR2963241B1
FR2963241B1 FR1056294A FR1056294A FR2963241B1 FR 2963241 B1 FR2963241 B1 FR 2963241B1 FR 1056294 A FR1056294 A FR 1056294A FR 1056294 A FR1056294 A FR 1056294A FR 2963241 B1 FR2963241 B1 FR 2963241B1
Authority
FR
France
Prior art keywords
vaccine against
gestational malaria
malaria
against gestational
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1056294A
Other languages
English (en)
Other versions
FR2963241A1 (fr
Inventor
Ndam Nicaise Tuikue
Philippe Deloron
Sedami Ursula Alix Carine Gnidehou
Mickael Quiviger
Pascal Bigey
Daniel Scherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Recherche pour le Developpement IRD
Original Assignee
Institut de Recherche pour le Developpement IRD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Recherche pour le Developpement IRD filed Critical Institut de Recherche pour le Developpement IRD
Priority to FR1056294A priority Critical patent/FR2963241B1/fr
Priority to EP11785071.9A priority patent/EP2598173B1/fr
Priority to US13/812,197 priority patent/US9540425B2/en
Priority to AP2013006749A priority patent/AP4023A/en
Priority to PCT/IB2011/002069 priority patent/WO2012014073A2/fr
Publication of FR2963241A1 publication Critical patent/FR2963241A1/fr
Application granted granted Critical
Publication of FR2963241B1 publication Critical patent/FR2963241B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
FR1056294A 2010-07-30 2010-07-30 Vaccin contre le paludisme gestationnel Expired - Fee Related FR2963241B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1056294A FR2963241B1 (fr) 2010-07-30 2010-07-30 Vaccin contre le paludisme gestationnel
EP11785071.9A EP2598173B1 (fr) 2010-07-30 2011-07-29 Vaccins dirigés contre le paludisme lié à la grossesse
US13/812,197 US9540425B2 (en) 2010-07-30 2011-07-29 Vaccines against pregnancy-associated malaria
AP2013006749A AP4023A (en) 2010-07-30 2011-07-29 Vaccines against pregnancy-associated malaria
PCT/IB2011/002069 WO2012014073A2 (fr) 2010-07-30 2011-07-29 Vaccins dirigés contre le paludisme lié à la grossesse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1056294A FR2963241B1 (fr) 2010-07-30 2010-07-30 Vaccin contre le paludisme gestationnel

Publications (2)

Publication Number Publication Date
FR2963241A1 FR2963241A1 (fr) 2012-02-03
FR2963241B1 true FR2963241B1 (fr) 2014-10-24

Family

ID=43920029

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1056294A Expired - Fee Related FR2963241B1 (fr) 2010-07-30 2010-07-30 Vaccin contre le paludisme gestationnel

Country Status (5)

Country Link
US (1) US9540425B2 (fr)
EP (1) EP2598173B1 (fr)
AP (1) AP4023A (fr)
FR (1) FR2963241B1 (fr)
WO (1) WO2012014073A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013217986B2 (en) * 2012-02-09 2017-04-27 Var2 Pharmaceuticals Aps Targeting of chondroitin sulfate glycans
EP2869838B1 (fr) * 2012-07-05 2020-09-02 Children's Medical Center Corporation Matrice de biofilm bactérien comme plateforme pour l'administration de protéines
FR3001152B1 (fr) * 2013-01-21 2015-12-04 Inst Rech Developpement Ird Combinaisons contre le paludisme gestationnel
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
CA2935064C (fr) * 2013-12-27 2023-06-27 Zymeworks Inc. Conjugues var2csa-medicament
US11197826B2 (en) * 2015-12-23 2021-12-14 Novartis Ag Oil-in-water emulsions including retinoic acid
US11071779B2 (en) 2016-06-17 2021-07-27 Children's Medical Center Corporation Biofilm matrix-boosted vaccine
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
WO2018235058A1 (fr) 2017-06-23 2018-12-27 Barcelona Institute For Global Health Système, procédé, appareil et test de diagnostic de grossesse

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE429929T1 (de) 1996-10-23 2009-05-15 Univ Pennsylvania Verbesserte impfstoffe
AU2003291977A1 (en) * 2003-01-27 2004-08-23 Kobenhavns Universitet Compounds useful in the diagnosis and treatment of pregnancy-associated malaria
US20090130136A1 (en) * 2004-09-30 2009-05-21 Miller Louis H Chondroitin Sulphate a Binding Domains
EP1885395A4 (fr) 2005-05-16 2009-12-02 Merck & Co Inc Procédé d'augmentation de l'immunigénicité des antigènes de plasmodium

Also Published As

Publication number Publication date
AP2013006749A0 (en) 2013-02-28
US20130129767A1 (en) 2013-05-23
FR2963241A1 (fr) 2012-02-03
EP2598173A2 (fr) 2013-06-05
US9540425B2 (en) 2017-01-10
EP2598173B1 (fr) 2018-04-18
WO2012014073A3 (fr) 2012-04-26
WO2012014073A2 (fr) 2012-02-02
AP4023A (en) 2017-02-02

Similar Documents

Publication Publication Date Title
DK3170508T3 (da) Vaccineformuleringer
FR2963241B1 (fr) Vaccin contre le paludisme gestationnel
ZA201401012B (en) Parenteral novovirus vaccine formulations
IL231043A0 (en) vaccine
EP2755680A4 (fr) Formulations vaccinales particulaires
IL222228A0 (en) Hiv vaccine
SMT201700046B (it) Micobatterio ricombinante come vaccino
ZA201300395B (en) Influenza vaccine
GB201119999D0 (en) Vaccine
HK1199199A1 (en) Blood stage malaria vaccine
FR2978048B1 (fr) Composition vaccinale contre le paludisme
EP2763699A4 (fr) Vaccin
DK2686011T3 (da) Ipn-vaccine
GB201014965D0 (en) Vaccine
ZA201403950B (en) Vaccine for falciparum malaria
ZA201404512B (en) Malaria vaccine
GB201120000D0 (en) Vaccine
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
ZA201302154B (en) Vaccine
AP2014007732A0 (en) Vaccine for falciparum malaria
GB201012283D0 (en) Vaccine
GB201007588D0 (en) Vaccine
GB201007589D0 (en) Vaccine
GB201121647D0 (en) Vaccine

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20200305